Asymptomatic carotid artery stenosis is associated with increased Alzheimer's disease and non-Alzheimer's disease dementia risk

被引:0
|
作者
Vitali, Francesca [1 ,2 ]
Torrandell-Haro, Georgina [2 ]
Branigan, Gregory [3 ]
Aristizabal, Juan Arias [4 ]
Reiman, Eric [5 ]
Bedrick, Edward J. [6 ]
Brinton, Roberta Diaz [2 ]
Weinkauf, Craig [4 ]
机构
[1] Univ Arizona, Coll Med, Neurol, Tucson, AZ USA
[2] Univ Arizona, Coll Med, Ctr Innovat Brain Sci, Tucson, AZ USA
[3] Univ Arizona, Coll Med, Tucson, AZ USA
[4] Univ Arizona, Coll Med, Dept Surg, Tucson, AZ 85724 USA
[5] Banner Alzheimers Inst, Phoenix, AZ USA
[6] Univ Arizona, Med Ctr, Ctr Biomed Informat & Biostat, Univ Campus, Tucson, AZ USA
关键词
Carotid Stenosis; Neurodegenerative Diseases; Risk Factors; Brain; History; COGNITIVE IMPAIRMENT; VASCULAR CONTRIBUTIONS; ATHEROSCLEROSIS; POPULATION; PREVALENCE; DYSFUNCTION; MANAGEMENT; STROKE;
D O I
10.1136/svn-2024-003164
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background In the absence of a cerebrovascular accident, whether asymptomatic extracranial carotid atherosclerotic disease (aECAD) affects Alzheimer's disease (AD) and non-AD dementia risk is not clear. Understanding whether aECAD is associated with an increased risk for AD is important as it is present in roughly 10% of the population over 60 and could represent a modifiable risk factor for AD and non-AD dementia. Methods This retrospective cohort study analysed Mariner insurance claims. Enrolment criteria included patients aged 55 years or older with at least 5 years of data and no initial dementia diagnosis. Subjects with and without aECAD were evaluated for subsequent AD and non-AD dementia diagnoses. Propensity score matching was performed using confounding factors identified by logistic regression. chi(2) tests and Kaplan-Meier survival curves were used to evaluate the impact of aECAD diagnosis on AD and non-AD dementia risk over time. Results 767 354 patients met enrolment criteria. After propensity score matching, 62 963 subjects with aECAD and 62 963 subjects without ECAD were followed through data records. The aECAD cohort exhibited an increased relative risk of 1.22 (95% CI 1.15 to 1.29, p<0.001) for AD and 1.48 (95% CI 1.38 to 1.59, p<0.001) for non-AD dementias compared with the propensity score-matched cohort without aECAD. The increased AD risk associated with aECAD was evident in patients younger than 75 years old and was less apparent in patients over 75 years of age. Conclusions aECAD is associated with an increased risk of developing AD and non-AD dementias. These findings underscore the need for further prospective evaluation of interactions between aECAD and dementia, with potential implications for change of clinical care in both of these large patient populations.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia
    Slot, Rosalinde E. R.
    Sikkes, Sietske A. M.
    Berkhof, Johannes
    Brodaty, Henry
    Buckley, Rachel
    Cavedo, Enrica
    Dardiotis, Efthimios
    Guillo-Benarous, Francoise
    Hampel, Harald
    Kochan, Nicole A.
    Lista, Simone
    Luck, Tobias
    Maruff, Paul
    Molinuevo, Jose Luis
    Kornhuber, Johannes
    Reisberg, Barry
    Riedel-Heller, Steffi G.
    Risacher, Shannon L.
    Roehr, Susanne
    Sachdev, Perminder S.
    Scarmeas, Nikolaos
    Scheltens, Philip
    Shulman, Melanie B.
    Saykin, Andrew J.
    Verfaillie, Sander C. J.
    Visser, Pieter Jelle
    Vos, Stephanie J. B.
    Wagner, Michael
    Wolfsgruber, Steffen
    Jessen, Frank
    van der Flier, Wiesje M.
    ALZHEIMERS & DEMENTIA, 2019, 15 (03) : 465 - 476
  • [2] Proton pump inhibitors and the risk of Alzheimer's disease and non-Alzheimer's dementias
    Torres-Bondia, Francisco
    Dakterzada, Farida
    Galvan, Leonardo
    Buti, Miquel
    Besanson, Gaston
    Gill, Eric
    Buil, Roman
    de Batlle, Jordi
    Pinol-Ripoll, Gerard
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [3] Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias
    Francisco Torres-Bondia
    Farida Dakterzada
    Leonardo Galván
    Miquel Buti
    Gaston Besanson
    Eric Gill
    Roman Buil
    Jordi de Batlle
    Gerard Piñol-Ripoll
    Scientific Reports, 10
  • [4] Neuroradiology of Non-Alzheimer's Disease Dementias
    Dai, Y. L.
    Wang, K.
    Cheung, T. C. Y.
    Dai, D. L. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (01): : 58 - 73
  • [5] Non-Alzheimer's disease dementias - Prologue
    Honig, LS
    Marder, K
    CLINICAL NEUROSCIENCE RESEARCH, 2004, 3 (06) : 347 - 348
  • [6] Homocysteine, antioxidant vitamins and lipids as biomarkers of neurodegeneration in Alzheimer's disease versus non-Alzheimer's dementia
    Raszewski, Grzegorz
    Chwedorowicz, Roman
    Chwedorowicz, Agnieszka
    Rothenberg, Katarzyna Gustaw
    ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE, 2016, 23 (01) : 193 - 196
  • [7] Non-Alzheimer's disease dementias - Epilogue
    Honig, LS
    Marder, K
    CLINICAL NEUROSCIENCE RESEARCH, 2004, 3 (06) : 481 - 481
  • [8] Neuroscintigraphy of Non-Alzheimer's Disease Dementias
    Wang, K.
    Dai, Y. L.
    Cheung, T. C. Y.
    Dai, D. L. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2015, 18 (01): : 74 - 86
  • [9] Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: Impact on non-Alzheimer's dementia?
    Rosler, N
    Wichart, I
    Bancher, C
    Jellinger, KA
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1996, (47): : 259 - 266
  • [10] Plasma Amyloid-β Forms in Alzheimer's Disease and Non-Alzheimer's Disease Patients
    Le Bastard, Nathalie
    Leurs, Judith
    Blomme, Walter
    De Deyn, Peter Paul
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 21 (01) : 291 - 301